Phase 1 N=52 A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
Neoplasms
Primary: Pharmacokinetics (PK) - Maximum Concentration (Cmax) of IMC-CS4 — 69.2; 6.83; 13.5; 26.0 Microgram/milliliters (µg/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal Neoplasms
Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
Phase 1 N=15 Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
Biological Availability · Healthy Participants
Primary: AUCinf of Nirmatrelvir Following the Administration of 4 Different Nirmatrelvir/Ritonavir FDC Tablets (Test Formulations) Compared to the Nirmatrelvir/Ritonavir…
Phase 1 N=8 Boiled Peanut Oral Immunotherapy
Peanut Hypersensitivity
Primary: Increase in Tolerance to Peanut in Pediatric Patients With Peanut Hypersensitivity Reported as the Percentage of Participants Successfully Desensitized. — 75 percentage…
Phase 1 N=12 Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function
Type 1 Diabetes
Primary: Change in the Gut Microbiome Profile — 818.5; 229; 1610; 177 species count
Phase 1 N=32 A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
Volunteers · Healthy
Primary: Adverse Events — 1; 2; 3; 2 Participants
Phase 1 N=9 Caffeine for Hypoxic-Ischemic Encephalopathy
Hypoxic-Ischemic Encephalopathy
Primary: Area Under Plasma Concentration-time at Time t (AUC0-t) for Caffeine — 1137.36; 1177.94; 2213.26; 2768.25 mg*hr/L
Phase 1 N=48 CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Granulocytic Sarcoma · Recurrent Adult Acute Myeloid Leukemia
Primary: Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as…
Phase 1 N=37 Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
Melanoma · BRAF V600 Mutation · Unresectable Melanoma
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time of Administration to Last Observed Plasma Concentration (AUClast) for Binimetinib — 1786; 1723 h*ng/mL
Phase 1 N=60 Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers
Healthy Subjects
Primary: Maximum Concentration (Cmax) — 29.9; 62.4; 70.5 Cmax ng/ml
Phase 1 N=10 Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
Hepatocellular Carcinoma
Primary: Number of Adverse Events — 12; 2; 8; 4 events
Phase 1 N=12 A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
Respiratory Syncytial Viruses
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants
Phase 1 N=15 A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
Solid Tumors, KRAS Mutation
Primary: Number of Patients With DLTs in the MTD Evaluation Period — 0; 0; 2 Participants
Phase 1 N=32 Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
HER2/Neu Negative · No Evidence of Disease · One or More Positive Axillary Nodes
Primary: Number of Adverse Events Per Common Terminology Criteria for Adverse Events Version 4.0 — 45; 53; 30; 2 Count of Related Adverse Events per Arm
Phase 1 N=114 A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.
Healthy Volunteers
Primary: Pharmacokinetics (PK) - (AUC[0-∞]) — 7500000; 8000000; 7520000 h*ng/ml